GLAXOSMITHKLINE UK LIMITED

Information

Name

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

http://uk.gsk.com/

Address

980 Great West Road Brentford, Middlesex

Brentford
TW8 9GS
United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with GLAXOSMITHKLINE UK LIMITED
Sign up free

Contracts awarded to GLAXOSMITHKLINE UK LIMITED

The contracts that GLAXOSMITHKLINE UK LIMITED have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 2 months ago

Measles, Mumps, Rubella and Varicella (MMRV) vaccine (2025)

Provision of measles, mumps, rubella and varicella (MMRV) vaccine (2025)

£2
Award

Published 2 months ago

NHS National Generic Pharmaceuticals Wave 15b

NHS National Pharmaceuticals Generic Products – Wave 15b Offer reference number: CM/PHG/23/5698 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/23/5698/01 – Orals (plus non-parenteral) Products CESW: (Midlands and Southwest): 1st October 2025 to 31st May 2027 (20 months) NWLN: (Northwest and London North): 1st October 2025 to 31st May 2027 (20 months) LSNE: (London South and Northeast): 1st October 2025 to 31st May 2027 (20 months) CM/PHG/23/5698/02 – Hospital Only Products DCE (Midlands) & DSW (Southwest): 1st October 2025 to 30th September 2027 (24 months) CM/PHG/23/5698/03 – Hospital Only (Housekeeping) Products DLS (London South) & DNE (Northeast): 1st October 2025 to 31st May 2026 (8 months) DNW (Northwest) & DLN (London North): 1st October 2025 to 31st January 2027 (16 months) DCE (Midlands) & DSW (Southwest): 1st October 2025 to 31st May 2026 (8 months)

£147
Award

Published 3 months ago

NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

£4,108,145,000 Bids close: 6 months ago
Award

Published 3 months ago

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

£24
Award

Published 3 months ago

NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National

NHS Framework Agreement for Branded Medicines - Tranche A London and South of England and Adult Influenza (National) - 01 September 2025 Offer reference number: CM/PHR/24/5718 CM/PHR/24/5718/01 - NHS Framework Agreement for Branded Medicines - Tranche A for London and South of England. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/24/5718/02 - NHS Framework Agreement for Branded Medicines - Adult Influenza (National). Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months.

£261,895,933 Bids close: 7 months ago
Award

Published 3 months ago

NHS Framework Agreement for Branded Medicines – Tranche A London and South of England and Adult Influenza (National) - 01 September 2025

NHS Framework Agreement for Branded Medicines – Tranche A London and South of England and Adult Influenza (National) - 01 September 2025 CM/PHR/24/5718/01 - NHS Framework Agreement for Branded Medicines – Tranche A for London and South of England. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5718/02 - NHS Framework Agreement for Branded Medicines – Adult Influenza (National). Period of Framework Agreement: 01 September 2025 to 31 August 2026

£29

GLAXOSMITHKLINE UK LIMITED

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to GLAXOSMITHKLINE UK LIMITED

Measles, Mumps, Rubella and Varicella (MMRV) vaccine (2025)

NHS National Generic Pharmaceuticals Wave 15b

NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National

NHS Framework Agreement for Branded Medicines – Tranche A London and South of England and Adult Influenza (National) - 01 September 2025

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win